← Back to headlines
ORIC Stock Rises as Stifel Resumes 'Buy' Rating Ahead of Pfizer Readout
ORIC Pharmaceuticals saw its stock gain after Stifel resumed its coverage with a 'Buy' rating, anticipating an upcoming readout from Pfizer.
12 Jun, 16:21 — 12 Jun, 16:21
Sources
Showing 1 of 1 sources
